Clinical trial Recruiting at 1 site Interventional Ages 25 to 55

Understanding what drives insulin resistance in healthy adults

Official title: sIgnatuRe: Defining the Human Insulin Resistance Molecular Network

Run by University of Copenhagen · NCT07255807 · Data updated 2026-11-12

This study tests how short-term changes in activity or diet affect insulin sensitivity in healthy adults to see if different people have different underlying causes.

Quick facts

Study typeInterventional
Ages25 Years to 55 Years
SexAll
Enrollment80 (estimated)
SponsorUniversity of Copenhagen
Academic / other
Locations1 site (Copenhagen)
StatusRecruiting
StartedJanuary 9, 2026
Main results expectedJune 30, 2028
Study endsJune 30, 2038
Registry record updatedAugust 17, 2026
Trial IDNCT07255807 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults 25–55 years old, BMI 18–30, healthy with no chronic diseases, non-smokers, and willing to adhere to study procedures.

Probably not a fit

Participants with chronic diseases, high baseline physical activity, or non-compliance may not experience direct benefits from the interventions.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Researchers will enroll 80 healthy adults aged 25–55 with BMI 18–30 to explore molecular subtypes of insulin resistance. After baseline phenotyping, participants are randomized to either a period of reduced physical activity for 14 days or a short-term high-fat diet for 3 days, then insulin sensitivity and related biomarkers are measured. The goal is to identify individual differences in the causes of insulin resistance and how lifestyle shifts influence these mechanisms. The study emphasizes a multi-omics approach to categorize sub-phenotypes and to inform personalized strategies for metabolic health.

Why it matters

Potential benefit: If successful, the study could help tailor lifestyle interventions based on an individual’s molecular profile to improve insulin sensitivity.

How similar studies have gone: Prior work suggests metabolic and molecular diversity in insulin resistance, though this study aims to finer-grain sub-phenotypes with controlled short-term lifestyle changes.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age: 25-55 years
* Body Mass Index (BMI): 18-30 kg/m²
* Healthy (no diagnosed chronic diseases)
* Able and willing to comply with study procedures

Exclusion Criteria:

* Smoking or nicotine use, current or within the past 5 years
* Alcohol intake exceeding 10 units per week
* Hemoglobin A1c (HbA1c) \> 48 mmol/mol (indicative of diabetes or prediabetes)
* Chronic diseases (e.g., cardiovascular disease, diabetes, etc.)
* Chronic medication use, including hormonal treatments
* High physical activity levels (more than 3 hours per week of moderate to vigorous exercise)
* Pregnancy or within 3 months postpartum
* Breastfeeding or within 3 months of cessation
* Abnormal routine blood markers (as defined in lab screening)
* Blood donation within the past 2 months

Where it's running

  • August Krogh Building
    Copenhagen, Denmark
    Recruiting

Study contacts

  • Principal investigator: Jørgen F.P. Wojtaszewski, Ph.D. — University of Copenhagen
  • Study coordinator: Jørgen F.P. Wojtaszewski, Ph.D.
  • Email: jw@nexs.ku.dk
  • Phone: +45 28751625

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.